Tango Therapeutics
Approach
Pipeline
Leadership
Join Us
Investors
Overview
News & Events
News Releases
Events & Presentations
Governance
Overview
Executive Leadership
Board of Directors
Committee Composition
Stock Information
Stock Quote & Chart
Financials
SEC Filings
Resources
Investor FAQs
Email Alerts
Contact IR
Contact
Home
Our Approach
Pipeline
Leadership
Join Us
Investors
▼
Overview
News & Events
▼
News Releases
Events & Presentations
Governance
▼
Overview
Executive Leadership
Board of Directors
Committee Composition
Stock Information
▼
Stock Quote & Chart
Financials
▼
SEC Filings
Resources
▼
Investor FAQs
Email Alerts
Contact IR
Contact
EGLN1 is a synthetic lethal target in ARID1A-mutant ovarian cancer
Press Release
EGLN1 is a synthetic lethal target in ARID1A-mutant ovarian cancer
